ATE401896T1 - Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern - Google Patents

Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern

Info

Publication number
ATE401896T1
ATE401896T1 AT99955428T AT99955428T ATE401896T1 AT E401896 T1 ATE401896 T1 AT E401896T1 AT 99955428 T AT99955428 T AT 99955428T AT 99955428 T AT99955428 T AT 99955428T AT E401896 T1 ATE401896 T1 AT E401896T1
Authority
AT
Austria
Prior art keywords
sulphamat
methoxyestron
pharmaceutical compositions
necrosis factor
tumor necrosis
Prior art date
Application number
AT99955428T
Other languages
English (en)
Inventor
Michael Reed
Barry Potter
Original Assignee
Sterix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812535.4A external-priority patent/GB9812535D0/en
Priority claimed from GBGB9910167.7A external-priority patent/GB9910167D0/en
Application filed by Sterix Ltd filed Critical Sterix Ltd
Application granted granted Critical
Publication of ATE401896T1 publication Critical patent/ATE401896T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99955428T 1998-06-10 1999-06-10 Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern ATE401896T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812535.4A GB9812535D0 (en) 1998-06-10 1998-06-10 Composition
GBGB9910167.7A GB9910167D0 (en) 1999-04-30 1999-04-30 Composition

Publications (1)

Publication Number Publication Date
ATE401896T1 true ATE401896T1 (de) 2008-08-15

Family

ID=26313837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99955428T ATE401896T1 (de) 1998-06-10 1999-06-10 Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern

Country Status (9)

Country Link
US (1) US6676934B1 (de)
EP (1) EP1085876B1 (de)
JP (1) JP2002517449A (de)
AT (1) ATE401896T1 (de)
AU (1) AU765386B2 (de)
CA (1) CA2334119C (de)
DE (1) DE69939171D1 (de)
ES (1) ES2310943T3 (de)
WO (1) WO1999064013A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127473A1 (en) * 1996-12-05 2004-07-01 Reed Michael John Compound
US7078395B1 (en) 1999-06-16 2006-07-18 Sterix Limited Methods for treating or preventing cancer by preventing, inhibiting or arresting cell cycling
JP5042411B2 (ja) * 1999-04-30 2012-10-03 ステリックス リミテッド 抗腫瘍剤としてのエストロン誘導体の使用
GB9913536D0 (en) * 1999-06-10 1999-08-11 Sterix Ltd Use
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
FR2806303B1 (fr) * 2000-03-17 2002-09-27 Inst Nat Sante Rech Med Composes capables de se lier a des proteines constituantes ou associees aux elements du cytosquelette et leurs applications pour la fabrication de medicaments
US20020106348A1 (en) * 2000-07-12 2002-08-08 Peng Huang Cancer therapeutics involving the administration of 2-methoxyestradiol and an agent that increases intracellular superoxide anion
WO2002015910A1 (en) 2000-08-18 2002-02-28 Sterix Limited 2-substituted estradiol derivative for inhibiting superoxid dismutase
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
GB0113920D0 (en) * 2001-06-07 2001-08-01 Sterix Ltd Composition
US20060051343A1 (en) * 2002-06-19 2006-03-09 Tatsuya Watanabe Preventives remedies for bone and joint diseases
DE10307105A1 (de) * 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte 18a-Homoestra-1,3,5(10)-trien-3-yl sulfamate
DE10307103A1 (de) * 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate
DE10307104A1 (de) * 2003-02-19 2004-09-23 Schering Ag Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate
WO2004085459A1 (en) 2003-03-24 2004-10-07 Sterix Limited Oestrogen derivatives as inhibitors of steroid sulphatase
GB0306717D0 (en) * 2003-03-24 2003-04-30 Sterix Ltd Compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9625334D0 (en) * 1996-12-05 1997-01-22 Imperial College Compound
US6011024A (en) * 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
GB9118478D0 (en) * 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
JPH0912596A (ja) * 1995-06-23 1997-01-14 Meiji Milk Prod Co Ltd 抗癌剤の腫瘍細胞障害作用を増強する新規な蛋白性因子
DE19540233B4 (de) * 1995-10-19 2005-08-25 Schering Ag Sulfamat-Derivate von 1,3,5(10)-Estratrien-Derivaten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
AU713341B2 (en) * 1996-09-12 1999-12-02 Teikoku Hormone Mfg. Co., Ltd. 3-substituted-d-homo-1,3,5,(10)-estratriene derivatives
US5880115A (en) * 1997-07-18 1999-03-09 Duquesne University Of The Holy Ghost Steroid sulfatase inhibitors and methods for making and using the same
GB2331988B (en) * 1997-12-04 2003-04-16 Imperial College Polycyclic sulphamate inhibitors or oestrone sulphatase
US6046186A (en) * 1997-12-24 2000-04-04 Sri International Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use

Also Published As

Publication number Publication date
DE69939171D1 (de) 2008-09-04
AU4280799A (en) 1999-12-30
EP1085876B1 (de) 2008-07-23
JP2002517449A (ja) 2002-06-18
CA2334119C (en) 2011-09-13
US6676934B1 (en) 2004-01-13
ES2310943T3 (es) 2009-01-16
EP1085876A1 (de) 2001-03-28
AU765386B2 (en) 2003-09-18
WO1999064013A1 (en) 1999-12-16
CA2334119A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
DE69939171D1 (de) Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern
DE69907977D1 (de) Pyrrolobenzodiazepine
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
ATE221887T1 (de) Substituierte 1,2,4-triazolo(3,4,-a)phthalazin- derivate als gaba-alpha 5-liganden
PT938471E (pt) A preparacao e uso de acidos ortosulfonamidoarilhidroxamicos como inibidores de metaloproteinases de matriz e "tace"
CA2276455A1 (en) Phthalazinones
MY124487A (en) Dolastatin derivatives, their preparation and use
DE69329425D1 (de) Dolastatin analog
PT889886E (pt) Novas fenantridinas substituidas na posicao 6
ATE307204T1 (de) Tumor-nekrose-faktor ähnliches ligand
NZ509244A (en) Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine, and/or phenylacetate
IT1285770B1 (it) Composti corticoidei
DE69728914D1 (de) Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
FI960658A0 (fi) Uudet bis-naftalimidit syövän hoitamiseksi
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
TR200101493T2 (tr) Eletriptan hidrobromid monohidrat
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
FI944563A0 (fi) Mikro-organismeja, valmistusmenetelmä ja käyttö
ES2179375T3 (es) Composiciones farmaceuticas estabilizadas, a base de quinupristina y de dalfopristina y su preparacion.
BR0317119A (pt) Agente antitumor, inibidor de proliferação celular, e, análogo de 3-fenil-cinolina
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
BR9306065A (pt) Composições mistas e bebida não aromatizadas de psyllium

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties